BIOMAT Database Logo BIOMAT Database Logo

Letter: Hemolytic anemia as adverse reaction to salicylazosulfapyridine. 1973

E P Gabor

UI MeSH Term Description Entries
D004912 Erythrocytes Red blood cells. Mature erythrocytes are non-nucleated, biconcave disks containing HEMOGLOBIN whose function is to transport OXYGEN. Blood Cells, Red,Blood Corpuscles, Red,Red Blood Cells,Red Blood Corpuscles,Blood Cell, Red,Blood Corpuscle, Red,Erythrocyte,Red Blood Cell,Red Blood Corpuscle
D005954 Glucosephosphate Dehydrogenase Glucose-6-Phosphate Dehydrogenase,Dehydrogenase, Glucose-6-Phosphate,Dehydrogenase, Glucosephosphate,Glucose 6 Phosphate Dehydrogenase
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000743 Anemia, Hemolytic A condition of inadequate circulating red blood cells (ANEMIA) or insufficient HEMOGLOBIN due to premature destruction of red blood cells (ERYTHROCYTES). Anemia, Hemolytic, Acquired,Anemia, Microangiopathic,Haemolytic Anaemia,Hemolytic Anemia,Hemolytic Anemia, Acquired,Microangiopathic Hemolytic Anemia,Acquired Hemolytic Anemia,Anaemia, Haemolytic,Anemia, Acquired Hemolytic,Anemia, Microangiopathic Hemolytic,Haemolytic Anaemias,Hemolytic Anemia, Microangiopathic,Microangiopathic Anemia,Microangiopathic Hemolytic Anemias
D012460 Sulfasalazine A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see MESALAMINE) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907) Salicylazosulfapyridine,Asulfidine,Azulfadine,Azulfidine,Azulfidine EN,Colo-Pleon,Pleon,Pyralin EN,Salazopyrin,Salazosulfapyridine,Sulfasalazin medac,Sulfasalazin-Heyl,Sulfasalazine FNA,Sulphasalazine,Ucine,Ulcol,ratio-Sulfasalazine,Colo Pleon,Sulfasalazin Heyl,ratio Sulfasalazine

Related Publications

E P Gabor
Pancreatitis as an adverse reaction to salicylazosulfapyridine.
February 1970, The New England journal of medicine,
E P Gabor
HEMOLYTIC ANEMIA SECONDARY TO SALICYLAZOSULFAPYRIDINE THERAPY.
October 1964, JAMA,
E P Gabor
Autoimmune hemolytic anemia, adverse event to venetoclax.
September 2019, Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria,
E P Gabor
Letter: Adverse reaction to flurazepam.
April 1975, Canadian Medical Association journal,
E P Gabor
[Hemolytic anemia with paradox reaction to cortisone].
January 1958, Folia haematologica (Leipzig, Germany : 1928),
E P Gabor
[Letter: Ovulation inhibitors in hemolytic anemia?].
November 1973, Deutsche medizinische Wochenschrift (1946),
E P Gabor
Letter: Coombs-test positive hemolytic anemia.
January 1976, The New England journal of medicine,
E P Gabor
Letter: An adverse reaction to althesin.
March 1974, British journal of anaesthesia,
E P Gabor
Letter: Salicylazosulfapyridine in clinical practice.
February 1974, Gastroenterology,
E P Gabor
Letter: Heparin: adverse reaction.
November 1973, Annals of internal medicine,
Copied contents to your clipboard!